Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 3039-3047

  Byrd, John C ^a   Jones, Jeffrey J ^a   Woyach, Jennifer A ^a   Johnson, Amy J ^a   Flynn, Joseph M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; METHYLPREDNISOLONE; OBINUTUZUMAB; OFATUMUMAB; PENTOSTATIN; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; VIDARABINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; CLINICAL PRACTICE; DRUG RESISTANCE; GENE DELETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROCEDURES; STANDARDS; TRENDS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; GENE DELETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; NITROGEN MUSTARD COMPOUNDS; PRACTICE PATTERNS, PHYSICIANS'; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINONES; VIDARABINE;

EID: 84907200622     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.8262     Document Type: Review

References (69)

1. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials-CLL Trialists' Collaborative Group. J Natl Cancer Inst 91:861-868, 1999
2. Motiwala T, Zanesi N, Datta J, et al.: AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 118:6132-6140, 2011
3. Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 24:437-443, 2006
4. Stevenson FK, Krysov S, Davies AJ, et al.: B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118:4313-4320, 2011
5. Woyach JA, Johnson AJ, Byrd JC: The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175-1184, 2012
6. Quiroga MP, Balakrishnan K, Kurtova AV, et al.: B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114:1029-1037, 2009
7. de Rooij MF, Kuil A, Geest CR, et al.: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590-2594, 2012
8. Herishanu Y, Pérez-Galán P, Liu D, et al.: The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia Blood 117:563-574, 2011
9. Klaus GG, Holman M, Johnson-Léger C, et al.: A re-evaluation of the effects of X-linked immunodeficiency (xid) mutation on B cell differentiation and function in the mouse. Eur J Immunol 27:2749-2756, 1997
10. Hendriks RW, de Bruijn MF, Maas A, et al.: Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. Embo J 15:4862-4872, 1996
11. Okkenhaug K, Bilancio A, Farjot G, et al.: Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034, 2002
12. Herman SE, Gordon AL, Wagner AJ, et al.: Phosphatidylinositol 3-kinase-delta inhibitor CAL- 101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078- 2088, 2010
13. Hoellenriegel J, Meadows SA, Sivina M, et al.: The phosphoinositide 3-kinase delta inhibitor, CAL- 101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118:3603-3612, 2011
14. Lannutti BJ, Meadows SA, Herman SE, et al.: CAL-101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117:591-594, 2011
15. Ponader S, Chen SS, Buggy JJ, et al.: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182- 1189, 2012
16. Herman SE, Gordon AL, Hertlein E, et al.: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI- 32765. Blood 117:6287-6296, 2011
17. Honigberg LA, Smith AM, Sirisawad M, et al.: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075-13080, 2010
18. Morrison VA: Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007:332-338, 2007
19. Morrison VA: The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25:98-106, 1998
20. Wadhwa PD, Morrison VA: Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240-249, 2006
21. Bergmann L, Fenchel K, Jahn B, et al.: Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371-375, 1993
22. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993
23. Kath R, Blumenstengel K, Fricke HJ, et al.: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48-54, 2001
24. Hosoda T, Yokoyama A, Yoneda M, et al.: Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma 54:1327- 1328, 2013
25. Krönke J, Udeshi ND, Narla A, et al: Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301-305, 2014
26. Galustian C, Meyer B, Labarthe MC, et al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033-1045, 2009
27. Ramsay AG, Johnson AJ, Lee AM, et al.: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437, 2008
28. Shanafelt TD, Ramsay AG, Zent CS, et al.: Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 121: 4137-4141, 2013
29. Woyach JA, Ruppert AS, Heerema NA, et al.: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349-1355, 2013
30. Tam CS, O'Brien S, Wierda W, et al.: Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
31. Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
32. Patton DT, Garden OA, Pearce WP, et al.: Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177:6598-6602, 2006
33. Dubovsky JA, Beckwith KA, Natarajan G, et al.: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539-2549, 2013
34. Roberts AW, Seymour JF, Brown JR, et al.: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496, 2013
35. Souers AJ, Leverson JD, Boghaert ER, et al.: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208, 2013
36. Blachly JS, Byrd JC: Emerging drug profile: Cyclin-dependent kinase inhibitors. Leuk Lymphoma 54:2133-2143, 2013
37. Byrd JC, Pagel JM, Awan FT, et al.: A phase 1 study evaluating the safety and tolerability of otlertuzumab (TRU-016), an anti-CD37 mono-specific ADAPTIRTM therapeutic protein in chronic lymphocytic leukemia. Blood 123:1302-1308, 2014
38. Lapalombella R, Yeh YY, Wang L, et al.: Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21:694- 708, 2012
39. Fischer K, Cramer P, Busch R, et al.: Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30:3209-3216, 2012
40. Kolibaba KS, Sterchele JA, Joshi AD, et al.: Demographics, treatment patterns, safety, and realworld effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: A retrospective study. Ther Adv Hematol 4:157-171, 2013
41. Hillmen P, Gribben JG, Follows GA, et al.: Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 32:1236- 1241, 2014
42. Foà R, Del Giudice I, Cuneo A, et al: Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 89: 480-486, 2014
43. Rafiq S, Butchar JP, Cheney C, et al.: Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol 190:2702-2711, 2013
44. Hillmen PR, Janssens A, Govindbabu K, et al.: Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): Results of the phase III study Complement. Blood 122, 2013 (abstr 528)
45. Goede V, Fischer K, Busch R, et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
46. O'Brien S, Furman RR, Coutre SE, et al.: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48-58, 2014
47. Byrd JC, O'Brien S, James DF: Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:1278-1279, 2013
48. Badoux XC, Keating MJ, Wen S, et al.: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118:3489- 3498, 2011
49. Chen CI, Bergsagel PL, Paul H, et al.: Singleagent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29:1175-1181, 2011
50. O'Brien SM, Lamanna N, Kipps TJ, et al.: A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS- 1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 31, 2013 (suppl 15s; abstr 7005)
51. Byrd JC, Rai K, Peterson BL, et al.: Addition of rituximab to fludarabine may prolong progressionfree survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005
52. Eichhorst B, Fink AM, Busch R, et al.: Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood 122, 2013 (abstr 21)
53. Pettitt AR, Jackson R, Carruthers S, et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 trial. J Clin Oncol 30: 1647-1655, 2012
54. Byrd JC, Furman RR, Coutre SE, et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013
55. Zelenetz AD, Wierda WG, Abramson JS, et al.: Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw 11:257-272, 2013; quiz 273
56. Advani RH, Buggy JJ, Sharman JP, et al.: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol 31:88- 94, 2013
57. Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111:5446- 5456, 2008
58. Woyach JA, Smucker K, Smith LL, et al.: Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123:1810-1817, 2014
59. Liu J, Fitzgerald ME, Berndt MC, et al.: Bruton tyrosine kinase is essential for botrocetin/VWFinduced signaling and GPIb-dependent thrombus formation in vivo. Blood 108:2596-2603, 2006
60. Quek LS, Bolen J, Watson SP: A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8:1137-1140, 1998
61. Futatani T, Watanabe C, Baba Y, et al.: Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol 114:141-149, 2001
62. Burger JA, Keating MJ, Wierda WG, et al.: Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): New, updated results of a phase II trial in 40 patients. Blood 122, 2013 (abstr 675)
63. Jaglowski SM, Jones JA, Flynn JM, et al.: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 30:418s, 2012 (suppl; abstr 6508)
64. Brown JR, Barrientos JC, Barr PM, et al.: Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: Final results of a phase 1b study. Blood 122, 2013 (abstr 525)
65. Brown JR, Furman RR, Flinn I, et al.: Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. J Clin Oncol 31, 2013 (suppl 15s; abstr 7003)
66. Barrientos JC, Furman RR, Leonard J, et al.: Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol 31, 2013 (suppl 15s; abstr 7017)
67. Furman RR, Sharman JP, Coutre SE, et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007, 2014
68. Porter DL, Levine BL, Kalos M, et al.: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
69. Woyach JA, Furman RR, Liu TM, et al.: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-2294, 2014